Skip to main navigation Skip to search Skip to main content

Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial.

  • Valentina Boni
  • , Mary J Fidler
  • , Hendrik-Tobias Arkenau
  • , Alexander Spira
  • , Funda Meric-Bernstam
  • , Nataliya Uboha
  • , Rachel E Sanborn
  • , Randy F Sweis
  • , Patricia LoRusso
  • , Misako Nagasaka
  • , Javier Garcia-Corbacho
  • , Shadia Jalal
  • , James J Harding
  • , Stella K Kim
  • , Iris H C Miedema
  • , Danielle J Vugts
  • , Marc C Huisman
  • , Gerben J C Zwezerijnen
  • , Guus A M S van Dongen
  • , Catharina W Menke-van der Houven van Oordt
    • Song Wang, Tam Dang, Ivan A Zein, Olga Vasiljeva, Susan K Lyman, Virginia Paton, Alison Hannah, Joyce F Liu

Research output: Contribution to journal › Article

Fingerprint

Dive into the research topics of 'Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial.'. Together they form a unique fingerprint.
Sort by

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science